Cliff Asness’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $27.1M | Sell |
332,251
-9,855
| -3% | -$712K | 0.01% | 1055 |
|
|
2026
Q1 | $23.3M | Buy |
342,106
+179
| +0.1% | +$12.7K | 0.01% | 974 |
|
|
2025
Q4 | $26M | Buy |
341,927
+10,671
| +3% | +$776K | 0.01% | 852 |
|
|
2025
Q3 | $20.3M | Sell |
331,256
-205,860
| -38% | -$10.7M | 0.01% | 846 |
|
|
2025
Q2 | $26.2M | Buy |
537,116
+124,093
| +30% | +$5.89M | 0.02% | 720 |
|
|
2025
Q1 | $21M | Buy |
413,023
+255,674
| +162% | +$12.8M | 0.02% | 686 |
|
|
2024
Q4 | $7.1M | Sell |
157,349
-32,230
| -17% | -$1.38M | 0.01% | 960 |
|
|
2024
Q3 | $7.03M | Buy |
189,579
+120,667
| +175% | +$4.04M | 0.01% | 917 |
|
|
2024
Q2 | $2.11M | Buy |
68,912
+52,019
| +308% | +$1.69M | ﹤0.01% | 1433 |
|
|
2024
Q1 | $491K | Sell |
16,893
-11,930
| -41% | -$334K | ﹤0.01% | 1967 |
|
|
2023
Q4 | $794K | Sell |
28,823
-81,578
| -74% | -$1.87M | ﹤0.01% | 1687 |
|
|
2023
Q3 | $2.47M | Buy |
110,401
+37,831
| +52% | +$1.41M | 0.01% | 1236 |
|
|
2023
Q2 | $2.95M | Buy |
72,570
+5,611
| +8% | +$275K | 0.01% | 1120 |
|
|
2023
Q1 | $3.24M | Buy |
66,959
+4,565
| +7% | +$209K | 0.01% | 1065 |
|
|
2022
Q4 | $2.38M | Buy |
62,394
+49,475
| +383% | +$2.06M | 0.01% | 1186 |
|
|
2022
Q3 | $649K | Buy |
12,919
+904
| +8% | +$44.3K | ﹤0.01% | 1684 |
|
|
2022
Q2 | $481K | Sell |
12,015
-23,960
| -67% | -$840K | ﹤0.01% | 1696 |
|
|
2022
Q1 | $1.34M | Buy |
35,975
+30,748
| +588% | +$1.18M | ﹤0.01% | 1397 |
|
|
2021
Q4 | $208K | Buy |
+5,227
| New | +$200K | ﹤0.01% | 2079 |
|
|
2021
Q2 | – | Sell |
-4,583
| Closed | -$217K | – | 2282 |
|
|
2021
Q1 | $217K | Sell |
4,583
-6,172
| -57% | -$367K | ﹤0.01% | 2096 |
|
|
2020
Q4 | $656K | Sell |
10,755
-17,029
| -61% | -$1M | ﹤0.01% | 1686 |
|
|
2020
Q3 | $1.3M | Sell |
27,784
-49,898
| -64% | -$2.46M | ﹤0.01% | 1289 |
|
|
2020
Q2 | $3.94M | Sell |
77,682
-8,976
| -10% | -$441K | 0.01% | 878 |
|
|
2020
Q1 | $3.87M | Sell |
86,658
-2,546
| -3% | -$128K | 0.01% | 867 |
|
|
2019
Q4 | $4.28M | Buy |
89,204
+54,175
| +155% | +$2.3M | ﹤0.01% | 1015 |
|
|
2019
Q3 | $1.19M | Sell |
35,029
-25,584
| -42% | -$1.11M | ﹤0.01% | 1477 |
|
|
2019
Q2 | $2.73M | Sell |
60,613
-182,015
| -75% | -$7.19M | ﹤0.01% | 1167 |
|
|
2019
Q1 | $9.13M | Sell |
242,628
-10,232
| -4% | -$344K | 0.01% | 806 |
|
|
2018
Q4 | $8.68M | Buy |
252,860
+141,602
| +127% | +$5.09M | 0.01% | 770 |
|
|
2018
Q3 | $5.23M | Buy |
111,258
+66,154
| +147% | +$2.74M | 0.01% | 985 |
|
|
2018
Q2 | $1.52M | Buy |
45,104
+27,526
| +157% | +$858K | ﹤0.01% | 1549 |
|
|
2018
Q1 | $476K | Sell |
17,578
-5,747
| -25% | -$146K | ﹤0.01% | 1927 |
|
|
2017
Q4 | $389K | Sell |
23,325
-50,289
| -68% | -$851K | ﹤0.01% | 1995 |
|
|
2017
Q3 | $1.47M | Buy |
73,614
+23,060
| +46% | +$451K | ﹤0.01% | 1509 |
|
|
2017
Q2 | $927K | Buy |
50,554
+38,330
| +314% | +$516K | ﹤0.01% | 1698 |
|
|
2017
Q1 | $120K | Buy |
+12,224
| New | +$148K | ﹤0.01% | 2152 |
|
|
2016
Q2 | – | Sell |
-85,397
| Closed | -$550K | – | 2248 |
|
|
2016
Q1 | $550K | Buy |
+85,397
| New | +$1.48M | ﹤0.01% | 1800 |
|
|
2015
Q4 | – | Sell |
-47,823
| Closed | -$1.28M | – | 2289 |
|
|
2015
Q3 | $1.28M | Sell |
47,823
-47,900
| -50% | -$2.05M | ﹤0.01% | 1320 |
|
|
2015
Q2 | $4.61M | Buy |
95,723
+13,447
| +16% | +$785K | 0.01% | 865 |
|
|
2015
Q1 | $5.01M | Buy |
82,276
+29,900
| +57% | +$1.82M | 0.01% | 778 |
|
|
2014
Q4 | $2.71M | Buy |
52,376
+9,676
| +23% | +$426K | 0.01% | 1148 |
|
|
2014
Q3 | $1.88M | Buy |
+42,700
| New | +$1.34M | 0.01% | 1297 |
|
Other funds holding PTCT
RI
JT
Cliff Asness's PTCT Position: Q2 2026 in Review
Cliff Asness reduced its PTC Therapeutics (PTCT) stake by 2.9% in Q2 2026, selling an estimated $712K and leaving 332,251 shares worth $27.1M. The position accounts for 0.01% of the portfolio, ranked #1055.
Cliff Asness first reported a position in PTCT in Q3 2014 and has held it in 42 quarters since. 380 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.
- Cliff Asness held 332,251 shares of PTC Therapeutics worth $27.1M as of Q2 2026.
- Cliff Asness sold 9,855 PTC Therapeutics shares in Q2 2026, an estimated $712K.
- PTC Therapeutics made up 0.01% of Cliff Asness's portfolio in Q2 2026, its #1055 holding.
- Cliff Asness first reported a position in PTC Therapeutics in Q3 2014 and has held it in 42 quarters since.
- 380 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.
Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.